Localized Prostate Cancer Articles & Analysis
3 articles found
Posluma (flotufolastat F 18) Posluma (flotufolastat F 18) is an 18F-labeled ligand and an imaging agent for the detection and localization of prostate cancer in PET (positron emission tomography). Posluma contains an imaging agent (18F) whose active ingredient is flotufolastat F 18 gallium bound to non-radioactive gallium. Flotufolastat F 18 ...
Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's ...
Background Since Walsh and Donker first introduced the anatomic nerve-sparing technique for retropubic radical prostatectomy1 (RRP) in the treatment of clinically localized prostate cancer, the importance of minimizing damage to the neurovascular bundle (NVB) has been recognized as a critical element for the preservation of potency and urinary ...